



Innovative
Training
Network

Grant Agreement number: **813986**

Acronym: **Syn2Psy**

Title: **Synaptic Dysfunction in Neuropsychiatric Disorders**

Report on network school 3

WP4 – D4.4 – D26

Contents

Introduction	3
Programme	4
Programme Table.....	5
Attendees.....	6
Certificate of Attendance.....	7
Course Satisfaction	8

Document Information

Deliverable Number	D4.4
Deliverable Title	Report on Network School 3 (NS3)
Work Package	WP4 – Training and Doctoral Programme
Lead Beneficiary	CNC
Type	Report
Dissemination Level	Public
Due Date	31-07-2021
Actual Deliverable Date	28-06-2021
Author	Raquel Rodrigues
Reviewed and Authorized	Ana Luísa Carvalho (coordinator)

Introduction

Network School 3 (NS3), under the title “**Drug discovery and development: from Idea to Patient**” was held online on May 5 – 7, 2021. This school was organized by Kjartan Herrik (Principle Scientist – Lundbeck).

NS3 was a three-day intensive course focused on the principles of drug development. Participants gained theoretical understanding on how Lundbeck and other pharmaceutical companies develop scientific ideas into treatments to help patients with neuropsychiatric disorders. Through the seminars on Pre-Clinical, Clinical and Business Development and Licensing, given by Lundbeck’s specialists, the Early Stage Researchers (ESRs) were taken through the steps from generating ideas to treating patients.

Furthermore, NS3 was complemented with a workshop on the early signs and clinical variability of Autism Spectrum Disorders, given by PIN (Syn2Psy Partner) and with seminars about the pros and cons of working in academia and industry, as well as a round table discussion about this topic.

As an evaluation, the ESRs were asked to pitch their project in the *Dragon’s Den*. This enabled the ESRs to communicate the potential value of their project for patients, commercial interests and the scientific community, as well as to understand what is needed from them to achieve these goals. *Dragons* were invited from Psychiatry, Industry and the Lundbeck Foundation.

To measure the overall course satisfaction, the students were asked to answer a satisfaction survey.

Programme



Drug discovery and development: from Idea to Patient – Lundbeck

Day 1 – May 5

- 09:00 – 10:00 **Introduction**
Kjartan Herrik, Principle Scientist, Lundbeck
- 10:00 – 11:00 **Work on Pitch**
- 11:00 – 12:00 **Idea to Molecule**
Jan Kehler, Research Fellow, Lundbeck
- 12:00 – 13:00 Virtual lunch
- 13:00 – 14:00 **Preclinical Research**
Niels Plath, Vice-President, Lundbeck
- 14:00 – 15:00 **Clinical Research**
Karina Strøjer Søby, Senior Project Director, Lundbeck
- 15:00 – 16:00 **BD&L – what to look for?**
Thomas Thestrup, Director, BD&L, Lundbeck
- 16:00 – 17:00 **Social**

Day 2 – May 6

- 09:00 – 10:00 **R&D Boardgame**
Benjamin Hall, Director, Lundbeck
Jesper Bastlund, Sr. Director, Lundbeck
Kjartan Herrik, Principle Scientist, Lundbeck
- 10:00 – 12:00 **PIN Workshop**
Carla Almeida, Special Education and Rehabilitation Technician
- 12:00 – 13:00 **Virtual lunch**

14:00 – 16:00 **Work on Pitch**

16:00 – 17:00 **Social**

Day 3 – May 7

09:00 – 12:00 **Dragon's Den**
 Andreas Jurgeit, Partner, GIMV
 Jesper Milman Jensen, Director, Pharmacosmos
 Rasmus Revsbech, Sr. Psychologist, Region Hovedstaden

12:00 – 13:00 **Virtual lunch**

13:00 – 14:00 **Working in academia and industry**
 Tarek Samad, Senior Vice President, Lundbeck

14:00 – 15:00 **Working with industry**
 Kristi Anne Kohlmeier, Ass. Professor, University of Copenhagen

15:00 – 16:00 **Industry versus academia**
 Roundtable discussion

16:00 – 17:00 **Social**

Programme Table

CEST/GMT+2	DAY 1 – May 5	DAY 2 – May 6	DAY 3 – May 7
9:00 – 10:00	Welcome	R&D Boardgame	Dragon's Den
10:00 – 11:00	Work on pitch	PIN workshop	
11:00 – 12:00	Idea to Molecule		
12:00 – 13:00	Virtual lunch	Virtual lunch	Virtual lunch
13:00 – 14:00	Preclinical Research	Work on pitch	Working in academia and industry
14:00 – 15:00	Clinical Research		Working with industry
15:00 – 16:00	BD&L - what to look for?		Industry versus academia
16:00 – 17:00	Social	Social	Social

Attendees

Students	Trainers, Speakers and Dragons
Orsolya Antal (ESR1)	Kjartan Herrik, Principle Scientist, Lundbeck
Alessandro Chioino (ESR2)	Jan Kehler, Research Fellow, Lundbeck
Giuseppe Cammarata (ESR3)	Niels Plath, Vice-President, Lundbeck
Veronica Villeri (ESR4)	Karina Strøjer Søby, Senior Project Director, Lundbeck
Marcos Sintes (ESR5)	Thomas Thestrup, Director, BD&L, Lundbeck
Daniel Hunter (ESR6)	Benjamin Hall, Director, Lundbeck
Elisa Corti (ESR7)	Jesper Bastlund, Sr. Director, Lundbeck
Elizabeth Brockman (ESR8)	Kjartan Herrik, Principle Scientist, Lundbeck
Flavio Tomasi (ESR10)	Carla Almeida, Special Education and Rehabilitation Technician
Ágata Silván (ESR11)	Andreas Jurgeit, Partner, GIMV
Manuela Rizzi (ESR12)	Jesper Milman Jensen, Director, Pharmacosmos
Loredana Cumpuna (ESR13)	Rasmus Revsbech, Sr. Psychologist, Region Hovedstaden
Vanesa Salazar (ESR14)	Tarek Samad, Senior Vice President, Lundbeck
Others	Kristi Anne Kohlmeier, Ass. Professor, University of Copenhagen
	Kim Fejgin, Research Scientist, Signal Transduction, Neuroscience, Lundbeck
	Others
	Catalina Betancur, Principal Investigator, IBPS




Figure 1: Early Stage Researchers during the workshop with PIN.

Certificate of Attendance



CERTIFICATE OF ATTENDANCE

NAME OF ESR

Participated with success in the **Syn2Psy Network School III**,

**DRUG DISCOVERY AND DEVELOPMENT:
FROM IDEA TO PATIENT**

TRAINING CONTENT (24 hours):

Idea to Molecule
Pre-clinical and Clinical research
Business Development and Licensing
Workshop on Autism Spectrum Disorder with PIN
Pitching of own project ideas against specialists within Psychiatry and Business Development
Workshop on strengths/weaknesses and potential when working within Academia and Industry



KJARTAN HERRIK



Course Satisfaction

The ESRs were asked to fill out a survey of 7 questions (Figures 2 and 3) and to give their opinion on the *Dragon's Den* challenge. The majority of the ESRs found the *Dragon's Den* to be a useful exercise since it provided the opportunity to convert each project into a proposal for the drug development industry and to look for the potential applications of their research. Other considerations included the fact that the *Dragon's Den* allowed the ESRs to address their projects from a new perspective, different to what is usual in basic research, and to learn how to communicate with potential collaborators. Furthermore, several ESRs considered that it was valuable to get feedback on their specific projects from a non-academic jury.




Figure 2. Course Satisfaction questionnaire and results.




Figure 2. Course Satisfaction questionnaire and results (continued).